Cannabis-Derived Substances in Cancer Therapy - An Emerging Anti-Inflammatory Role for the Cannabinoids
This article reviews the ever-changing relationship between cannabinoids and cancer, and updates our understanding of this class of agent. Furthermore, the relationship between chronic inflammation and cancer, and how cannabinoids can impact this relationship will be described.
Keywords: AEA; AKT; BAX/BIM; CBR1; CBR2; CBRs; Cancer Therapy; Cannabinoids; Cannabis; Carcinogenesis; Ceramide Messaging System; Crohn's disease; Helicobacter pylori; IFN-α; Inflammation; JNK signalling; MDM2; PI3-K pathways; PI3-K/AKT; anandamide; apoptosis; c-JUN Kinase (JNK) Pathway; cannabis plant; cytarabine; diphosphatidylglycerol; doxorubicin; immune modulation; inflammation; inositol triphosphate signalling pathways; mTOR; neoplasia; oxaliplatin; prima facie; rheostat; rheumatoid arthritis; tetrahydrocannabinol; vascularisation; vincristine
Document Type: Research Article
Publication date: November 1, 2010
- Current Clinical Pharmacology publishes frontier reviews on all the latest advances in clinical pharmacology. The journal's aim is to publish the highest quality review articles in the field. Topics covered include: pharmacokinetics; therapeutic trials; adverse drug reactions; drug interactions; drug metabolism; pharmacoepidemiology; and drug development. The journal is essential reading for all researchers in clinical pharmacology.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites